BerGenBio ASA

LSE:0RU5 Stock Report

Market Cap: NOK 390.1m

BerGenBio Valuation

Is 0RU5 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0RU5 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0RU5's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0RU5's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0RU5?

Key metric: As 0RU5 barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0RU5. This is calculated by dividing 0RU5's market cap by their current book value.
What is 0RU5's PB Ratio?
PB Ratio2.5x
BookNOK 153.38m
Market CapNOK 390.05m

Price to Book Ratio vs Peers

How does 0RU5's PB Ratio compare to its peers?

The above table shows the PB ratio for 0RU5 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average4.1x
HEMO Hemogenyx Pharmaceuticals
4.3xn/aUK£13.1m
ETX e-therapeutics
1.9xn/aUK£52.6m
TRX Tissue Regenix Group
1.7x170.8%UK£40.6m
PBX ProBiotix Health
8.3xn/aUK£10.7m
0RU5 BerGenBio
2.5x-23.6%NOK 390.1m

Price-To-Book vs Peers: 0RU5 is good value based on its Price-To-Book Ratio (2.5x) compared to the peer average (4.3x).

Price to Book Ratio vs Industry

How does 0RU5's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.46m
VAL ValiRx
0.6xn/aUS$2.78m
No more companies available in this PB range
0RU5 2.5xIndustry Avg. 2.9xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0RU5 is good value based on its Price-To-Book Ratio (2.5x) compared to the UK Biotechs industry average (2.9x).

Price to Book Ratio vs Fair Ratio

What is 0RU5's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0RU5 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.5x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0RU5's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0RU5 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentNOK 9.90
NOK 20.00
+102.0%
68.2%NOK 38.00NOK 5.00n/a3
Nov ’25NOK 8.55
NOK 20.00
+133.9%
68.2%NOK 38.00NOK 5.00n/a3
Oct ’25NOK 10.28
NOK 20.00
+94.6%
68.2%NOK 38.00NOK 5.00n/a3
Sep ’25n/a
NOK 20.00
0%
68.2%NOK 38.00NOK 5.00n/a3
Aug ’25NOK 13.16
NOK 30.67
+133.0%
92.1%NOK 70.00NOK 5.00n/a3
Jul ’25NOK 11.87
NOK 33.33
+180.8%
81.5%NOK 70.00NOK 5.00n/a3
Jun ’25NOK 14.28
NOK 33.33
+133.4%
81.5%NOK 70.00NOK 5.00n/a3
May ’25n/a
NOK 76.67
0%
114.2%NOK 200.00NOK 5.00n/a3
Apr ’25NOK 19.05
NOK 76.67
+302.5%
114.2%NOK 200.00NOK 5.00n/a3
Mar ’25NOK 19.52
NOK 76.67
+292.7%
114.2%NOK 200.00NOK 5.00n/a3
Feb ’25NOK 26.80
NOK 76.67
+186.1%
114.2%NOK 200.00NOK 5.00n/a3
Jan ’25NOK 27.85
NOK 76.67
+175.3%
114.2%NOK 200.00NOK 5.00n/a3
Dec ’24NOK 17.90
NOK 76.67
+328.4%
114.2%NOK 200.00NOK 5.00n/a3
Nov ’24NOK 19.80
NOK 568.33
+2,770.4%
116.8%NOK 1,500.00NOK 5.00NOK 8.553
Oct ’24NOK 10.68
NOK 568.33
+5,221.5%
116.8%NOK 1,500.00NOK 5.00NOK 10.283
Sep ’24NOK 11.32
NOK 568.33
+4,920.6%
116.8%NOK 1,500.00NOK 5.00n/a3
Aug ’24NOK 10.04
NOK 1,501.67
+14,856.8%
81.4%NOK 3,000.00NOK 5.00NOK 13.163
Jul ’24NOK 9.10
NOK 1,533.33
+16,749.8%
77.2%NOK 3,000.00NOK 100.00NOK 11.873
Jun ’24NOK 38.43
NOK 1,533.33
+3,889.7%
77.2%NOK 3,000.00NOK 100.00NOK 14.283
May ’24NOK 184.80
NOK 1,533.33
+729.7%
77.2%NOK 3,000.00NOK 100.00n/a3
Apr ’24n/a
NOK 1,800.00
0%
49.1%NOK 3,000.00NOK 900.00NOK 19.053
Mar ’24n/a
NOK 1,800.00
0%
49.1%NOK 3,000.00NOK 900.00NOK 19.523
Feb ’24NOK 677.50
NOK 1,800.00
+165.7%
49.1%NOK 3,000.00NOK 900.00NOK 26.803
Jan ’24n/a
NOK 1,800.00
0%
49.1%NOK 3,000.00NOK 900.00NOK 27.853
Dec ’23NOK 893.28
NOK 1,800.00
+101.5%
49.1%NOK 3,000.00NOK 900.00NOK 17.903
Nov ’23NOK 825.50
NOK 1,200.00
+45.4%
25.0%NOK 1,500.00NOK 900.00NOK 19.802

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

1.3%

1Y

13.6%

Regeneron Pharmaceuticals

US$79.4b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$745.13

7D

-2.1%

1Y

-6.5%